The Marketing Authorisation for Intrinsa (Testosterone 300 microgram per 24 hour transdermal patch) was recently cancelled with the European Medicines Agency. 

The reason for this cancellation was purely commercial and was not due to any safety concerns.

Intrinsa is now an unlicenced medicine. HFA Healthcare have secured stock for the foreseeable future and can supply the product as an unlicenced medicine within MHRA guidelines. 

Product Information

European Medicine Agency Public Statement

Intrinsa EPAR update


Unlicenced Diltiazem Hydrochloride 20mg/g Cream